To investigate whether theophylline reduces the incidence of contrast-media-induced nephropathy we performed a randomised, placebo-controlled, double-blinded study. Primary endpoint was to compare the incidence of contrast-nephropathy in high-risk-patients after administration of intravenous theophylline-prophylaxis (200mg/70kg body weight; n=50) with a placebo-controlled group (n=50). The incidence was signifcantly lower in the theophylline-group vs. the placebo-group (4% vs 16%, p=0,0406). Further, there was no significant rise of serum-creatinine or urine-ß-NAG after theophylline-application. Multiple-regression-analysis identified risk-factors for a rise in serum-creatinine-level after contrast-media application.
«
To investigate whether theophylline reduces the incidence of contrast-media-induced nephropathy we performed a randomised, placebo-controlled, double-blinded study. Primary endpoint was to compare the incidence of contrast-nephropathy in high-risk-patients after administration of intravenous theophylline-prophylaxis (200mg/70kg body weight; n=50) with a placebo-controlled group (n=50). The incidence was signifcantly lower in the theophylline-group vs. the placebo-group (4% vs 16%, p=0,0406). Fu...
»